{"id":"naltrexone-block","safety":{"commonSideEffects":[{"effect":"Fatigue","drugRate":"15.4%","placeboRate":"","totalAtRisk":39,"totalAffected":6,"trialsReporting":2},{"effect":"Dizziness/drowsiness","drugRate":"17.4%","placeboRate":"","totalAtRisk":23,"totalAffected":4,"trialsReporting":1},{"effect":"Nausea, gastrointestinal discomfort, vomiting.","drugRate":"13.0%","placeboRate":"","totalAtRisk":23,"totalAffected":3,"trialsReporting":1},{"effect":"Shaking","drugRate":"4.3%","placeboRate":"","totalAtRisk":23,"totalAffected":1,"trialsReporting":1},{"effect":"Asymptomatic non-sustained ventricular tachycardia","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Catheter-related asymptomatic uncomplicated right upper extremity superficial venous thrombophlebiti","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Presyncopal episode, likely vasovagal response","drugRate":"0.0%","placeboRate":"","totalAtRisk":32,"totalAffected":0,"trialsReporting":2},{"effect":"Right lower lung subcentimeter pleural based nodular density","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Incidental PET CT- Right upper lung subcentimeter nodule associated with hypermetabolism","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Incidental PET CT- Nonspecific subpleural nodules","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Nausea","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Feels foggy","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Drowsy","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Feels edgy","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1},{"effect":"Headache","drugRate":"0.0%","placeboRate":"","totalAtRisk":16,"totalAffected":0,"trialsReporting":1}]},"_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T05:16:55.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:21:01.111780+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06500793","phase":"PHASE1","title":"Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)","status":"RECRUITING","sponsor":"Ensysce Biosciences","startDate":"2024-11-24","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT01950520","phase":"PHASE2","title":"Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-07","conditions":"Healthy Volunteers","enrollment":47},{"nctId":"NCT02454712","phase":"PHASE1","title":"Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2016-11-16","conditions":"Healthy","enrollment":64},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT04757506","phase":"NA","title":"An Investigation of the Effects of Opioid Receptor Blockade on Changes in Self-esteem and Social Attention","status":"COMPLETED","sponsor":"McGill University","startDate":"2012-07-09","conditions":"Self Esteem","enrollment":35},{"nctId":"NCT04322526","phase":"PHASE4","title":"Study of Naltrexone-Induced Blockade of Antidepressant Effects","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2017-07-01","conditions":"Depression, Major Depressive Disorder","enrollment":25},{"nctId":"NCT02088177","phase":"PHASE1, PHASE2","title":"Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-10","conditions":"Cannabis Dependence","enrollment":12},{"nctId":"NCT01822132","phase":"NA","title":"Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2013-05","conditions":"Methamphetamine Abuse, HIV","enrollment":76},{"nctId":"NCT02911597","phase":"PHASE1","title":"Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-09","conditions":"Depression","enrollment":16},{"nctId":"NCT01210638","phase":"PHASE1","title":"Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2008-06","conditions":"Pain","enrollment":42},{"nctId":"NCT00992095","phase":"NA","title":"Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2006-08","conditions":"Opioid-Related Disorders","enrollment":48},{"nctId":"NCT00577408","phase":"PHASE3","title":"Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opiate Dependence, Heroin Dependence","enrollment":60},{"nctId":"NCT01721070","phase":"PHASE1","title":"Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics","status":"COMPLETED","sponsor":"Talphera, Inc","startDate":"2012-11","conditions":"Pharmacokinetics","enrollment":19},{"nctId":"NCT02117583","phase":"PHASE1","title":"Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT02165930","phase":"PHASE1","title":"Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-07","conditions":"Healthy","enrollment":17},{"nctId":"NCT02089295","phase":"PHASE1","title":"Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT02059915","phase":"PHASE1","title":"Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":134},{"nctId":"NCT01462227","phase":"NA","title":"Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-08","conditions":"Hypoglycemia","enrollment":17},{"nctId":"NCT01717027","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-11","conditions":"Healthy","enrollment":19},{"nctId":"NCT01552850","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-04","conditions":"Pain","enrollment":18},{"nctId":"NCT01924676","phase":"PHASE1","title":"Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-08","conditions":"Healthy","enrollment":18},{"nctId":"NCT01552863","phase":"PHASE1","title":"A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-03","conditions":"Pain","enrollment":21},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01557257","phase":"PHASE1","title":"Pharmacokinetics Study of ALO-02 and OxyContin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Management of Moderate to Severe Pain","enrollment":13},{"nctId":"NCT01319266","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment","status":"COMPLETED","sponsor":"Cephalon","startDate":"2011-03","conditions":"Renal Impairment","enrollment":55},{"nctId":"NCT00399295","phase":"PHASE1","title":"An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Analgesia","enrollment":30},{"nctId":"NCT00042536","phase":"","title":"Effects of Yohimbine and Naltrexone on Sexual Function","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-07","conditions":"Erectile Dysfunction","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Naltrexone block","genericName":"Naltrexone block","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":7,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:21:01.111780+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}